Abstract p53, encoded by the tumor suppressor gene TP53, is one of the most important
tumor suppressor factors in vivo and can be negatively regulated by MDM2 through p53 …

Since its discovery over 35 years ago, MDM2 has emerged as an attractive target for the
development of cancer therapy. MDM2's activities extend from carcinogenesis to immunity to …

The MDM2 and MDMX (also known as HDMX and MDM4) proteins are deregulated in many
human cancers and exert their oncogenic activity predominantly by inhibiting the p53 tumour …

The tumour suppressor p53 is the most frequently mutated gene in human cancer, with more
than half of all human tumours carrying mutations in this particular gene. Intense efforts to …

Design of small-molecule inhibitors (MDM2 inhibitors) to block the MDM2–p53 protein–
protein interaction has been pursued as a new cancer therapeutic strategy. In recent years …

Inhibition of protein–protein interactions (PPIs) represents a significant challenge because it
is unclear how they can be effectively and selectively targeted using small molecules …

Since Hedin's characterization of trypsin and antitrypsin in 1906,(1) arguably the first
account of a regulatory protein–protein interaction (PPI), contemporary understanding of …

MDM2 is a primary cellular inhibitor of p53. It inhibits p53 function by multiple mechanisms,
each of which, however, is mediated by their direct interaction. It has been proposed that …

The emergence and convergence of cancer genomics, targeted therapies, and network
oncology have significantly expanded the landscape of protein–protein interaction (PPI) …

Blocking the oncoprotein murine double minute 2 (MDM2)–p53 protein–protein interaction
has long been considered to offer a broad cancer therapeutic strategy, despite the potential …